MEET QPS AT AD/PD™ 2024; March 5-9, Lisbon, Portugal

Amorfix Aggregated Aβ Assay (A4 Assay)

Generation of amyloid-beta peptide (Aβ) species and their aggregation into highly neurotoxic oligomers and fibrils is one of the major hallmarks of Alzheimer’s disease (AD).

The A4 (Amorfix Aggregated Abeta Assay) – exclusively licensed to QPS Austria – serves as a unique screening tool, which enables the fast, highly sensitive and cost efficient detection of Aβ oligomers in diverse biological samples.

Importantly, the A4 has translational value due to its unmatched sensitivity and applicability in various sample types. The same method can be used to:

  • determine the mechanism of action and to identify your lead compound in an in vitro screening.
  • detect Aβ oligomers in samples from transgenic animal models.
  • measure Aβ oligomers in clinical samples.
Assay format:
  • 96 well
  • Electrochemiluminescence
  • Brain homogenates
  • In vitro aggregated Aβ
  • CSF
  • Any

Reduction of Aβ aggregation in hAPP transgenic mice treated with a β-secretase (BACE) inhibitor and a vaccine, respectively. (A) Dose-dependent effect of a novel BACE inhibitor on aggregated Aβ species in hippocampi of 8 months old male hAPPwt mice. Shown are mean + SEM, n=5. (B) Effect of a vaccine on aggregated Aβ species in hemibrains of 16 months old APP/Tg2576 mice. Shown are mean + SEM, n=8.